YungShin Global Holding Corp.
TTWSE:370559.10
TWD
+0.20
(+0.34%)
ISIN
TW0003705000
Return %
Stock
S&P 500
1Y
1.55
14.20
3Y
34.01
81.12
5Y
37.12
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Kuo Hun Yin
- Full Time Employees
- 11
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1191 Taipei TPE Taiwan 10541
- IPO Date
- Jan 3, 2011
- Website
- yungshingroup.com
- Similar Companies
- Business
- YungShin Global Holding Corporation operates primarily as a holding company managing a diverse portfolio of pharmaceutical and health-related businesses. Founded in 1960 and headquartered in Taipei, Taiwan, the group focuses on the research, development, manufacturing, and marketing of pharmaceutical products. Its core product lines include active pharmaceutical ingredients (APIs); human prescription drugs; over-the-counter (OTC) healthcare products; animal health medicines through its subsidiary Vetnostrum Animal Health; and health and beauty care products. YungShin integrates capabilities across API production, intermediate chemical manufacturing, formulation development, and global sales, serving markets including Taiwan, China, the U.S., Japan, Southeast Asia, Australia, Africa, and New Zealand. The company has recently pursued vertical integration and horizontal expansion strategies to enhance competitiveness, including the acquisition of Pfizer’s Hsinchu manufacturing plant, entering the feed additives market, and expanding into OEM manufacturing through acquisitions of Alpha-Active and Taiwan Wa-Chein Industrial Co., Ltd. It has also invested in biotechnology via partnerships to acquire manufacturing technology from GlyTech Inc. and is exploring advanced fields like biomedicine and cell therapy. Organizational restructuring in 2022 aimed at resource integration and operational efficiency underpins these strategic moves. Additionally, YungShin has expanded its generic drug offerings in Japan by acquiring active pharmaceutical ingredients from JAC and notably consolidated its animal health segment under Vetnostrum. Overall, YungShin Global Holding is positioned as a leading global generic pharmaceutical group, leveraging decades of expertise alongside recent operational expansions and technological acquisitions to grow its footprint across traditional pharmaceutical, animal health, and wellness markets internationally. It remains committed to innovation, resource maximization, and market expansion as part of its vision to be among the top global generic pharmaceutical firms within the next decade. The company also engages in health promotion activities including medical research grants and senior care services, reflecting a holistic approach to health beyond pharmaceuticals.